# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
BMO Capital analyst Kostas Biliouris maintains Centessa Pharmaceuticals (NASDAQ:CNTA) with a Outperform and raises the price...
Centessa Pharmaceuticals plc (NASDAQ:CNTA), today announced that preclinical data from a non-human primate (NHP) study of ORX14...
Oppenheimer analyst Francois Brisebois reiterates Centessa Pharmaceuticals (NASDAQ:CNTA) with a Outperform and maintains $14...
Centessa Pharmaceuticals (NASDAQ:CNTA) reported quarterly losses of $(0.40) per share which missed the analyst consensus estima...
Oppenheimer analyst Francois Brisebois initiates coverage on Centessa Pharmaceuticals (NASDAQ:CNTA) with a Outperform rating...
Morgan Stanley analyst Matthew Harrison maintains Centessa Pharmaceuticals (NASDAQ:CNTA) with a Equal-Weight and raises the ...
Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicine...